Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers

Abstract Background Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) is associated wit...

Full description

Bibliographic Details
Main Authors: Françoise Derouane, Manon Desgres, Camilla Moroni, Jérôme Ambroise, Martine Berlière, Mieke R. Van Bockstal, Christine Galant, Cédric van Marcke, Marianela Vara-Messler, Stefan J. Hutten, Jos Jonkers, Larissa Mourao, Colinda L. G. J. Scheele, Francois P. Duhoux, Cyril Corbet
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Breast Cancer Research
Subjects:
Early triple negative breast cancer
Neoadjuvant chemotherapy
Organoids
Metabolism
Glycolysis
Therapy resistance
Online Access:https://doi.org/10.1186/s13058-024-01788-8

Internet

https://doi.org/10.1186/s13058-024-01788-8

Similar Items